1-3 of 3
M. Renee Ward, MD, PhD
Close
Sort by
Journal Articles

Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study

Guillermo Garcia-Manero, MD, Steven D. Gore, MD, Christopher R. Cogle, MD, Elias J. Jabbour, MD, M. Renee Ward, MD, PhD, Kyle J. MacBeth, PhD, Eric Laille, MS, Heidi Giordano, MA, Hagop M. Kantarjian, MD, Barry S. Skikne, MD
Journal: Blood
Blood (2010) 116 (21): 603.
https://doi.org/10.1182/blood.V116.21.603.603
Published: 2010
Journal Articles

A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), Results From a Phase 1 Study.

Kyle J MacBeth, Eric Laille, Yuhong Ning, Christopher R. Cogle, MD, Barry Skikne, Steven D. Gore, MD, Guillermo Garcia-Manero, MD, M. Renee Ward, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1772.
https://doi.org/10.1182/blood.V114.22.1772.1772
Published: 2009
Journal Articles

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).

Guillermo Garcia-Manero, MD, Steven D. Gore, MD, Barry Skikne, Christopher R. Cogle, MD, Yuhong Ning, Kyle J MacBeth, Eric Laille, M. Renee Ward, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 117.
https://doi.org/10.1182/blood.V114.22.117.117
Published: 2009